Trump Signs Order to Accelerate Psychedelic Research and Access in the US

Former President Donald Trump has signed an executive order directing federal agencies to accelerate research into psychedelic substances and expand access to experimental treatments, marking a significant shift in U.S. Drug policy that could reshape clinical approaches to mental health disorders. The order, issued in late April 2024, instructs the Department of Health and Human Services (HHS), the Food and Drug Administration (FDA), and the National Institutes of Health (NIH) to streamline regulatory pathways for studying substances like psilocybin, MDMA, and ibogaine, particularly for veterans and first responders suffering from treatment-resistant depression, PTSD, and substance employ disorders.

While the move has drawn attention for its alignment with growing bipartisan interest in psychedelic-assisted therapy, it also raises questions about the scope of presidential authority over drug scheduling and the balance between innovation and safety. The order does not deschedule or legalize these substances but aims to reduce bureaucratic hurdles for clinical trials and expanded access programs under existing federal frameworks such as the FDA’s Expanded Access program and Breakthrough Therapy designation.

According to the White House fact sheet released alongside the order, the administration cites rising suicide rates among military personnel and limited efficacy of conventional antidepressants as key motivators. The directive emphasizes the need for “rigorous, science-based evaluation” of psychedelics’ therapeutic potential while maintaining safeguards against misuse. Officials involved in drafting the order referenced preliminary data from NIH-funded studies showing remission rates exceeding 60% in some psilocybin-assisted therapy trials for major depressive disorder.

The order specifically tasks the FDA with issuing guidance within 90 days on how institutional review boards (IRBs) can approve psychedelic research protocols more efficiently, and directs the NIH to prioritize funding for Phase 2 and 3 trials targeting PTSD and addiction. It also instructs the Veterans Affairs (VA) Department to explore partnerships with academic medical centers to provide supervised psychedelic-assisted therapy to eligible veterans through existing research protocols.

Policy Context and Regulatory Boundaries

Psychedelics such as psilocybin (found in certain mushrooms), MDMA, and ibogaine remain classified as Schedule I substances under the Controlled Substances Act, meaning they are deemed to have a high potential for abuse and no currently accepted medical use under federal law. This classification imposes strict limits on research, requiring special registration with the Drug Enforcement Administration (DEA) and adherence to stringent security and reporting protocols.

The executive order does not alter this scheduling status but seeks to work within the current legal framework by directing agencies to use existing authorities to facilitate research. For example, the FDA can grant Expanded Access to investigational drugs for patients with serious or life-threatening conditions when no comparable alternatives exist, and the NIH can fund studies that comply with DEA regulations.

Experts note that while presidential directives can influence agency priorities, they cannot override congressional statutes or international treaties like the 1971 Convention on Psychotropic Substances, which the U.S. Has ratified. Any permanent change to the legal status of psychedelics would require action by Congress or a formal rescheduling petition reviewed by the FDA and DEA.

“This order reflects a growing recognition that we need to explore all evidence-based options for mental health care, especially for those who have served our country,” said Dr. Joshua Gordon, Director of the National Institute of Mental Health (NIMH), in a statement to Reuters following the announcement. “But it must be done rigorously, with attention to safety, dosing, and long-term outcomes.”

Scientific Background and Clinical Evidence

Interest in psychedelic-assisted therapy has grown significantly over the past decade, driven by clinical trials conducted at institutions such as Johns Hopkins University, Imperial College London, and the Multidisciplinary Association for Psychedelic Studies (MAPS). Phase 2 trials of MDMA-assisted psychotherapy for PTSD, sponsored by MAPS, showed that 67% of participants no longer met diagnostic criteria for PTSD after 18 weeks, compared to 32% in the placebo group, according to results published in Nature Medicine in 2021.

Similarly, a 2022 Johns Hopkins study found that two doses of psilocybin, combined with supportive psychotherapy, produced rapid and sustained reductions in depressive symptoms in adults with major depressive disorder, with effects lasting up to 12 months in some participants. These findings contributed to the FDA granting Breakthrough Therapy designation to both psilocybin (for depression) and MDMA (for PTSD) in recent years.

Ibogaine, a psychoactive compound derived from the root bark of the West African shrub Tabernanthe iboga, has garnered attention for its potential to interrupt opioid and alcohol dependence, though its use carries cardiovascular risks, including QT interval prolongation, which can lead to serious arrhythmias. Due to these safety concerns, ibogaine remains unapproved in the U.S. And is largely studied in offshore clinics in Mexico, Canada, and New Zealand.

The executive order does not endorse any specific substance but directs agencies to evaluate the totality of evidence. It also calls for increased monitoring of adverse events in research settings and the development of standardized training protocols for therapists involved in psychedelic-assisted sessions.

Stakeholder Reactions and Implementation Challenges

The order has elicited cautious optimism from researchers and advocacy groups. Organizations such as the Psychedelic Science Funders Collaborative and Veterans Exploring Treatment Solutions (VETS) welcomed the move as a step toward reducing stigma and expanding access to promising therapies. “For too long, veterans have been forced to seek treatment abroad or through underground networks,” said Marcus Capone, CEO of VETS, in an interview with The Hill. “This order acknowledges the urgency of the crisis and the potential of these medicines when used responsibly.”

However, some public health officials and drug policy experts have urged caution. Dr. Nora Volkow, Director of the National Institute on Drug Abuse (NIDA), emphasized in a briefing to congressional staff that while preliminary data are encouraging, long-term safety profiles, potential for misuse, and equitable access must be rigorously studied before widespread adoption. She noted that historical patterns show that enthusiasm for novel psychoactive substances can outpace evidence, citing the 1960s-era psychedelic research boom that was halted due to safety and societal concerns.

Implementation faces practical barriers, including the limited number of manufacturers capable of producing pharmaceutical-grade psychedelics under current DEA quotas, the need for specialized training of clinicians, and inconsistent state-level regulations. While cities like Oakland and Denver have decriminalized certain psychedelics at the municipal level, federal law still prohibits possession and distribution outside of approved research contexts.

The order requires agencies to report progress to the White House within 180 days, including recommendations for any additional executive or regulatory actions. Observers will be watching closely to see whether this leads to increased NIH grant awards, updated FDA guidance, or expanded VA partnerships in the coming months.

What Which means for Patients and Providers

For individuals suffering from treatment-resistant mental health conditions, the order signals a potential expansion of access to investigational therapies through legal, medically supervised channels. Patients interested in participating in clinical trials can search for ongoing studies via ClinicalTrials.gov, using keywords such as “psilocybin depression,” “MDMA PTSD,” or “ibogaine addiction.”

Healthcare providers should note that administering psychedelics outside of FDA-approved trials or Expanded Access programs remains illegal under federal law and could result in professional licensing actions or criminal liability. The DEA continues to enforce Schedule I regulations, and unauthorized possession or distribution carries severe penalties.

The administration has not announced plans to establish a federal psychedelic therapy program or to fund treatment outside of research settings. Any future expansion of access would likely depend on the outcomes of ongoing clinical trials and potential future FDA approvals, which, if granted, would allow prescription use under strict medical supervision.

As the federal government navigates this evolving landscape, the emphasis remains on balancing innovation with patient safety. The coming months will be critical in determining whether this executive order catalyzes a new era in psychiatric research or remains a limited directive with modest operational impact.

For updates on federal psychedelic research initiatives, readers can monitor announcements from the NIH Office of Disease Prevention and the FDA’s Center for Drug Evaluation and Research. Public comment periods may be opened for proposed guidance documents, offering opportunities for stakeholders to contribute to the shaping of policy.

We encourage readers to share their perspectives on this development in the comments below and to spread awareness of evidence-based mental health innovations by sharing this article with others who may benefit.